Ziad Taib

Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials.

Eva-Marie Andersson, C. Ämmälä, J. Leander, 2020, The Lancet. Rheumatology.

Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.

Geoff J M Parker, Lars E Olsson, Caleb Roberts, 2014, European journal of radiology.

Objectively identified comorbidities in COPD: impact on pulmonary rehabilitation outcomes

E. Wouters, F. Pitta, M. Spruit, 2015, European Respiratory Journal.

Efficacy and Tolerability of an Inhaled Selective Glucocorticoid Receptor Modulator – AZD5423 – in Chronic Obstructive Pulmonary Disease Patients: Phase II Study Results

P. Kuna, C. Jorup, S. Edsbäcker, 2017, Basic & clinical pharmacology & toxicology.

COPD biomarkers as tools for decision making in early clinical drug development.

A. Jauhiainen, Z. Taib, Ziad Taib, 2016, Biomarkers in medicine.

The development of AZD7624 for prevention of exacerbations in COPD: a randomized controlled trial

Steven, B. Make, S. Rennard, 2018, International journal of chronic obstructive pulmonary disease.

Study on risk factors and phenotypes of acute exacerbations of chronic obstructive pulmonary disease in Guangzhou, China-design and baseline characteristics.

Rongchang Chen, N. Zhong, P. Ran, 2015, Journal of thoracic disease.